7TPS
Crystal structure of ALPN-202 (engineered CD80 vIgD) in complex with PD-L1
Summary for 7TPS
Entry DOI | 10.2210/pdb7tps/pdb |
Descriptor | T-lymphocyte activation antigen CD80, Programmed cell death 1 ligand 1, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, ... (8 entities in total) |
Functional Keywords | co-stimulatory, ig-like, v-type, t-cell, proliferation, immune system |
Biological source | Homo sapiens (human) More |
Total number of polymer chains | 4 |
Total formula weight | 76208.22 |
Authors | Demonte, D.W.,Maurer, M.F.,Akutsu, M.,Kimbung, Y.R.,Logan, D.T.,Walse, B. (deposition date: 2022-01-26, release date: 2022-03-16, Last modification date: 2023-10-18) |
Primary citation | Maurer, M.F.,Lewis, K.E.,Kuijper, J.L.,Ardourel, D.,Gudgeon, C.J.,Chandrasekaran, S.,Mudri, S.L.,Kleist, K.N.,Navas, C.,Wolfson, M.F.,Rixon, M.W.,Swanson, R.,Dillon, S.R.,Levin, S.D.,Kimbung, Y.R.,Akutsu, M.,Logan, D.T.,Walse, B.,Swiderek, K.M.,Peng, S.L. The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity. Nat Commun, 13:1790-1790, 2022 Cited by PubMed: 35379805DOI: 10.1038/s41467-022-29286-5 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (3.15 Å) |
Structure validation
Download full validation report